Table 2 Predicted drug susceptibility scores of efavirenz, doravirine, rilpivirine and etravirine
Efavirenz | Susceptible | Low-level resistance | Intermediate resistance | High-level resistance |
|---|---|---|---|---|
| Â | Etravirine | Â | Â | Â |
Susceptible (36) | 34 (94.4%) | 2 (5.6%) | 0 (0%) | 0 (0%) |
Low level resistance (1) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Intermediate resistance (2) | 1 (50%) | 0 (0%) | 1 (50%) | 0 (0%) |
High level resistance (142) | 36 (25.2%) | 33 (23.2%) | 49 (34.5%) | 25 (17.6%) |
Total (182) | 72 (39.2%) | 35 (19.3%) | 50 (27.6%) | 25 (13.8%) |
| Â | Rilpivirine | Â | Â | Â |
Susceptible (36) | 34 (94.4%) | 2 (5.6%) | 0 (0%) | 0 (0%) |
Low level resistance (1) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Intermediate resistance (2) | 1 (50%) | 0 (0%) | 1 (50%) | 0 (0%) |
High level Resistance (142) | 36 (25.2%) | 33 (23.2%) | 49 (34.5%) | 25 (17.6%) |
Total (182) | 72 (39.2%) | 35 (19.3%) | 50 (27.6%) | 25 (13.8%) |
| Â | Doravirine | Â | Â | Â |
Susceptible (36) | 36 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Low level resistance (1) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Intermediate resistance (2) | 1 (50%) | 0 (0%) | 1 (50%) | 0 (0%) |
High level Resistance (142) | 22 (15.4%) | 23 (16.1%) | 54 (37.8%) | 44 (30.8%) |
Total (182) | 60 (33%) | 23 (12.6%) | 55 (30.2%) | 44 (24.2%) |